Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Weill Cornell Medicine researchers have received a five-year, $6.2 million grant from the National Institute on Aging, part of the National Institutes ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...